246 related articles for article (PubMed ID: 9587129)
21. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Dent S; Eapen L; Girard A; Hugenholtz H; DaSilva V; Stewart DJ
J Neurooncol; 1996 Apr; 28(1):25-30. PubMed ID: 8740588
[TBL] [Abstract][Full Text] [Related]
22. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
[TBL] [Abstract][Full Text] [Related]
23. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma.
Masaki Y; Miki M; Sun Y; Nakamura T; Iwao H; Nakajima A; Kurose N; Sakai T; Jin ZX; Sawaki T; Kawanami T; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H
Int J Hematol; 2011 Jun; 93(6):720-726. PubMed ID: 21573892
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
26. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
28. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
29. Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol.
Schürmann D; Grünewald T; Weiss R; Jautzke G; Pohle HD; Ruf B
Eur J Haematol; 1995 Feb; 54(2):73-7. PubMed ID: 7535244
[TBL] [Abstract][Full Text] [Related]
30. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
Bessell EM; Graus F; López-Guillermo A; Villá S; Verger E; Petit J; Holland I; Byrne P
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):457-64. PubMed ID: 11380234
[TBL] [Abstract][Full Text] [Related]
31. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.
Kobayashi T; Tobinai K; Shimoyama M; Mikuni C; Konda S; Kozuru M; Araki K; Sai T; Fukuhara S; Matsumoto M; Aoki I; Deura K; Oyama A; Hotta T; Abe T; Toki H; Nagai M; Fukuda H; Niimi M; Yamaguchi N; Tajima K; Shirakawa S
Jpn J Clin Oncol; 1999 Jul; 29(7):340-8. PubMed ID: 10470659
[TBL] [Abstract][Full Text] [Related]
33. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
34. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
[TBL] [Abstract][Full Text] [Related]
35. Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study.
Goldkuhl C; Ekman T; Wiklund T; Telhaug R;
Acta Oncol; 2002; 41(1):29-35. PubMed ID: 11990514
[TBL] [Abstract][Full Text] [Related]
36. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
37. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
38. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen.
Avilés A; Nambo MJ; Halabe J
Ann Hematol; 1999 Jan; 78(1):9-12. PubMed ID: 10037262
[TBL] [Abstract][Full Text] [Related]
39. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
40. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
